Antiserum against tumor necrosis factor-alpha and a protease Inhibitor reduce immune glomerular injury. Previous studies in this laboratory have documented tumor necrosis factor alpha (TNF) release by macrophage laden glomeruli in the accelerated autologous form of nephrotoxic serum nephritis (AA-NTSN). We now report that the administration of anti-TNF antiserum to rats with the AA-NTSN reduces albuminuria in a dose related manner (day 8 postinduction) and limits glomerular necrosis (P < 0.05) without affecting the endogenous creatinine clearance (Ccr). Protease inhibitors block cytolytic activity of TNF in vitro and reduce glomerular necrosis in experimental nephritis in vivo. The combined administration of anti-TNF antiserum and an amidine-type protease inhibitor (BABIM) to rats with the AA-NTSN caused a greater diminution of albuminuria and histopathology than observed in rats treated with either agent alone, and also prevented the fall in Ccr otherwise observed in this model system.
reduce immune glomerular injury. Previous studies in this laboratory have documented tumor necrosis factor alpha (TNF) release by macrophage laden glomeruli in the accelerated autologous form of nephrotoxic serum nephritis (AA-NTSN). We now report that the administration of anti-TNF antiserum to rats with the AA-NTSN reduces albuminuria in a dose related manner (day 8 postinduction) and limits glomerular necrosis (P < 0.05) without affecting the endogenous creatinine clearance (Ccr). Protease inhibitors block cytolytic activity of TNF in vitro and reduce glomerular necrosis in experimental nephritis in vivo. The combined administration of anti-TNF antiserum and an amidine-type protease inhibitor (BABIM) to rats with the AA-NTSN caused a greater diminution of albuminuria and histopathology than observed in rats treated with either agent alone, and also prevented the fall in Ccr otherwise observed in this model system.
Since, in our studies, BABIM did not inhibit cytolytic TNF activity in vitro, we conclude that the effects of combined administration of these two agents are mediated by independent mechanisms. Our results highlight the pathogenic significance of local TNF release in immune renal disease accompanied by prominent glomerular macrophage accumulation.
The pathogenesis of glomerular injury in experimental nephritis induced by the injection of heterologous antiserum to the glomerular basement membrane has been attributed to a broad array of soluble inflammatory mediators. Thus, complement components [1] , coagulation factors [2] , proteolytic enzymes [3, 4] , oxygen radicals [5] and the myeloperoxide/hydrogen peroxide/halide system [6] all have been implicated in glomerular injury during the neutrophil dependent, heterologous phase of nephrotoxic serum nephritis. Conversely, glomerular injury observed during the later, autologous phase of the disease occurs in the absence of neutrophuls and complement and is clearly dependent on local accumulation of mononuclear phagocytes [7] . Though macrophages are known to release a variety of inflammatory mediators [8] , the pathogenesis of macrophagedependent glomerulonephritis remains ill defined.
We have recently documented release of TNF by glomeruli isolated from LEW rats with the AA-NTSN [9] . TNF initially described as a macrophage product capable of inducing hemorrhagic necrosis of solid tumors [10] , was subsequently shown to be identical to cachectin, identified in sera of animals with Received for publication September 20, 1990 and in revised form February Il, 1991 Accepted for publication February 12, 1991 © 1991 by the International Society of Nephrology chronic infections [11] . Numerous reports have appeared lately to suggest that TNF is a potent inflammatory and immunoregulatory mediator. It stimulates procoagulant activity in vascular endothelium [12] , induces collagenase and prostaglandin secretion by synovial cells [13] , activates neutrophils [14] and macrophages [15] , enhances immune responses in vitro [15] and in vivo [16] . More recently TNF has been shown to cause vascular damage when injected in the skin of normal mice together with bacteria in reaction dependent upon the fifth component of complement [17] .
In the present study we have administered anti-TNF antiserum to rats with the AA-NTSN, a model noted to be associated with glomerular macrophage accumulation, to assess the role of TNF in the pathophysiology of glomerular injury in this model system. Further, since protease inhibitors are reported to reduce cytotoxicity of TNF in vitro [18] and to mitigate glomerular necrosis in experimental nephritis in vivo, possibly through intreference with inflammatory mediators such as the plasma contact system [19] , additional studies have been performed to determine whether the apparent beneficial effect of protease antagonists in experimental nephritis could be linked to modulation of TNF activity.
Methods

Animals
Inbred male LEW rats weighing 200 to 250 g were obtained from Harlan Sprague-Dawley (Indianapolis, Indiana, USA) and male New Zealand White rabbits (2 to 2.5 kg), from Cunipur (St. Hyacinthe, Quebec, Canada).
Characterization of the experimental nephritis model under study
The AA-NTSN was induced in LEW rats as previously described [20] . Briefly, rats were immunized intraperitoneally on day -5 with sheep immunoglobulin G (500 sg) emulsified in 0.5 ml of Complete Freund's Adjuvant (CFA). On day 0, a subnephritogenic dose (0.05 ml) of sheep anti-rat glomerular basement membrane (GBM) antiserum was administered through the dorsal penile vein. This regimen induces proliferative endo-and extracapillary glomerulonephritis with focal fibrin deposition, necrosis, focal disruption of the GBM and occasional crescent formation. Immunofluorescence studies reveal linear deposition of heterologous immunoglobulin along the GBM. A transient neutrophil infiltration is noted on day 1 postinduction, to be replaced (day 2 to 3) by a prominent glomerular macrophage accumulation [7] , and this latter phase has been linked with the onset of proteinuria. Generally, disease in this model system is self-limited, proteinuria so induced falling to negligible levels within 10 to 12 days.
Antiserum against recombinant murine TNF-alpha (rMuTNF) Rabbits were inoculated with 10 jig of rMuTNF (provided by Dr. H.M. Shepard, Genentech Laboratories, San Francisco, California, USA) emulsified in CFA at multiple subcutaneous sites and two weeks later received 10 jig rMuTNF in Incomplete Freund's Adjuvant. Thereafter rabbits were boosted biweekly with rMuTNF (10 jig) in phosphate buffered saline (PBS) over a six month period. A test bleed was performed prior to each injection and sera recovered were tested and/or stored at -85°C.
Activity of anti-TNF antiserum was quantitated in immunoprecipitation and neutralization assays. Briefly, rMuTNF was radiolabelled to an activity of 4 X iO cpmlng (1251, New England Nuclear, Boston, Massachusetts, USA) by the iodogen method [21] and immunoprecipitated as described by Beutler, Milsark and Cerami [22] . Antisera were serially diluted (1/1 to 1/10) in PBS containing 1% bovine serum albumin (BSA). Twenty microliter aliquots were incubated with 0.2 ng 1251.. rMuTNF at 4°C for five hours. Thereafter, 10 jil of Staphylococcus Protein A (ICN Immunobiologicals, Lisle, Illinois, USA) diluted 1/5 with distilled water was added to each tube and these incubated for further 30 minutes at room temperature. Samples were then diluted with 1 ml PBS/l%-BSA, sedimented in a Brinkmann microfuge, supernatants aspirated and the radioactivity of pellets counted with a gamma spectrometer (Tri-Carb, Packard).
Neutralizing activity of anti-rMuTNF antiserum was determined by quantitating inhibition of cytolysis of sensitive L929 cells effected by rMuTNF or by culture supernatants of glomeruli isolated from rats with AA-NTSN previously shown to contain TNF [9] . In the latter instance glomeruli were isolated from LEW on day 3 of the AA-NTSN by differential seiving [23] and cultured 24 hours in RPMI 1640 medium in 80 cm2 flasks at 1000 glomeruli/mI. Recombinant MuTNF (10 pg/mI) and filtered supernatants (125 jil) were preincubated (1 hr, room temperature) with serial dilutions of preimmune and immune anti-TNF antisera and residual cytotoxic activity assessed in 96-well plates, each well of which contained 3 x io L929 cells prelabelled with 3H-methyl thymidine (10 jiCi/106 cells) in a total volume of 250 jil of RPM! 1640, 10% FBS. After 72 hours incubation (37°C, 100% humidity, 5% C02) 200 jil aliquots of culture media were harvested and radioactivity counted in a beta scintillation counter (Minaxi, Tri-Carb, Packard).
Isolation of the IgG fraction of anti-TNF antiserum Ammonium sulfate precipitation, dialysis and gel filtration (Sephadex G-200, Pharmacia Fine Chemicals, Dorval, Quebec, Canada) were performed as described by Garvey, Cremer and Sussdorf [24] to yield 6.4 mg IgG per ml of crude antiserum.
Albuminuria. Urinary albumin excretion was quantitated by radial immunodiffusion assay [20] . Percent inhibition of albuminuria by various in vivo manipulations was calculated as follows:
% inhibition = 100 x [(mean albuminuria control rats -albuminuria of a rat treated with inhibitor):mean albuminuna control rats] Endogenous creatinine clearance. Serum and urine creatinine concentrations were determined with an autoanalyzer (Astra, Beckman) and endogenous creatinine clearance (Ce,., mI/mm) calculated by dividing creatinine excretion (mg/mm) by the plasma creatinine concentration (mg/mi).
Histology and immunofluorescence. Renal tissue was excised, blocks were cut and these were variously fresh frozen or fixed either in 3.7% buffered formalin for light microscopy (LM) or 2.5% glutaraldehyde for electron microscopy (EM). Three micron sections of paraffin-embedded LM specimens were stained with hematoxylin and eosin as well as periodic acid silver-methyamine. Encoded slides were examined independently by two pathologists (K.S. and S.J.) and the number of glomeruli showing necrotic changes, fibrin deposition or crescent formation determined as a percentage of at least 200 glomeruli examined on multiple widely separated sections.
Frozen tissue specimens were evaluated by direct immunofluorescence using fluorescein isothiocyanate conjugated goat anti-rabbit IgG F(ab)2 and C3, as well as goat anti-rat IgG F(ab)2, C3 and 1gM (all from Organon Teknika, Scarborough, Ontario, Canada). After rinsing in PBS (45 mm, 25°C) preparations were examined under UV epiillumination.
Assay of autologous rat anti-sheep antibody. Titers of circulating antibody to sheep IgG were determined by solid phase radiometric assay, as previously described [20] , with sera prediluted 1/64 in buffer.
Experimental design. The AA-NTSN was induced in nine groups of rats according to the following protocol:
Experiments I and II. In each experiment 10 rats with the AA-NTSN were randomly allocated to treatment (N = 5) and control groups (N = 5). Two hundred microliters of anti-TNF or nonimmune rabbit serum (NRS), diluted 1/4 with PBS, were administered i.p., five hours prior to the intravenous injection of sheep anti-GBM antiserum (day 0), and continued daily until the end of experiment (day 8). Twenty-four hour urine collections were obtained on days 3 to 4 and 7 to 8 post-induction. Rats were exsanguinated under ether anaesthesia on day 8 and the sera recovered were retained for creatinine and anti-sheep IgG measurements. Kidneys were excised for histopathological studies as above.
Experiment ill. Increasing doses of anti-TNF antiserum were administered to three groups of rats with the AA-NTSN (N = 5/group) as follows: Group A, 0.05 ml; B, 0.2 ml; C, 0.5 ml. Control rats (N = 5, group D) were inoculated with 0.5 ml of NRS on a daily basis.
Experiment IV. The IgG fractions of anti-TNF or NRS were administered to rats daily (treatment and control groups, N = 5), commencing the day of nephritis induction and effects on albuminuria/renal function assessed.
Experiment V. In order to determine whether the administration of crude NRS affected either the induction or course of the AA-NTSN, NRS (0.2 ml diluted 1/4 in PBS) was given to 8 rats with the AA-NTSN as above and subsequent albuminuna and Cr compared to those observed in AA-NTSN rats receiving saline alone (N = 8).
Experiments VI-VIJI. Additional studies were carried out to assess the effects of a protease inhibitor in this model system. On day 3 animals were exsanguinated, samples of kidney, liver and lung tissues obtained, and specific activities determined using a gamma counter.
Effect of BABIM on cytotoxic activity of rMuTNF in vitro The cytotoxic activity of rMuTNF (10 pg/mI) on L929 cells was assessed in 96-well plates essentially as described above, in the presence or absence of BABIM (10-n M to 10 '°M). Briefly, BABIM was dissolved in distilled water, filtered sterile and dilutions were added to triplicate either to target cells in media alone or to the cells incubated in presence of rMuTNF.
Statistical signflcance Statistical significance was calculated using the Student's t-test. Additionally, the Bonferroni Method, a simultaneous multiple comparison procedure [25] was employed to assess more adequately the significance of differences among experimental groups in values of albuminuria and creatinine clearances.
Results
Activity of anti-TNF antiserum The precipitating and neutralizing activities of rabbit antisera against rMuTNF in this study are illustrated in Figures 1 and 2, respectively. Precipitating activity reached a peak at three months after the initial immunization (50% precipitation at approximately 1:8000 dilution) and subsequently declined. Conversely, neutralizing activity of such sera climbed to 50% with a 1:4000 dilution at three months and increased thereafter with repeated boosts to a titer of 1:32,000 at five months only to remain at this level till the end of the study (Fig. 2A) . As illustrated in Figure 2B , the anti-TNF antiserum generated in this study fully inhibited cytotoxic activity of culture supernatants of nephritic glomeruli at similar dilutions.
Effect of anti-TNF on albuminuria and Ce,.
As illustrated in Table 1 (Experiment 1), anti-TNF antiserum significantly reduced albuminuria of rats with the AA-NTSN as measured on days 3 to 4 and 7 to 8 following nephritis induction (P < 0.0025 and P < 0.0005, respectively; mean suppression day 3 to 4, 42.9% 17.4%; day 7 to 8, 53.6% 14.2%). This reduction could not be attributed to a fall in glomerular filtration in the anti-TNF group, since Cr on days 4 and 8 in both groups were insignificantly different (day 4, anti-TNF, 0.66 0.10 ml/min; NRS 0.72 0.11 mI/mm; day 8, anti-TNF, 0.52 0.24 ml/min; NRS 0.51 0.19 mllmin; mean SD).
These results were confirmed in an additional experiment (Exp. II) consisting of six treated and control nephritic rats (data not shown). Overall suppression of albuminuria in these experiments on days 3 to 4 and 7 to 8 were as follows: day 4, 46.8% 21.3%, day 8, 47.9% 23.9%, N = 11).
Dose dependent effect of anti-TNF in AA-NTSN The effects of graded doses of anti-TNF antiserum (0.05 ml, 0.2 ml, 0.5 ml), administered daily, on albuminuria on day 8 following induction of the AA.NTSN were examined in Experiment III. Administration of 0.05 ml antiserum reduced albuminuria 45%, but this effect was not significant due to the large variability of the response. Conversely, albuminuria was reduced by 39.3% and 65.9% in rats treated with 0.2 ml and 0.5 mI/day, respectively, the higher dose being significantly more effective. C. values were equivalent in all groups. As an additional control we noted that Cr of rats with Method, P <0.00014). The simultaneous multiple comparison procedure (Bonferroni Method) was utilized in statistical eva!-uation to control the error rate associated with the whole set of comparisons. In each experiment a combination of anti-TNF and BABIM caused a greater fall in albuminuria than did either agent alone. In pooled data from these three experiments the difference between anti-TNF and anti-TNF + BABIM groups was significant, whereas the comparison between groups treated with BABIM and anti-TNF + BABIM yielded P values below the borderline of significance (Bonferroni Method, P < 0.04 and P < 0.08, respectively). Albuminuria was reduced 78% by day 8 in AA-NTSN rats treated with both anti-TNF antiserum and BABIM (N = 14).
As illustrated in Figure 4 , AA-NTSN rats treated with anti-TNF and BABIM demonstrated a striking preservation of Cr on day 8 following nephritis induction, while Cr of rats treated with anti-TNF or BABIM alone were equivalent to NRS/PBS controls (Bonferroni Method, anti-TNF + BABIM vs. NRS, P <0.00014; anti-TNF + BABIM vs. anti-TNF, P < 0.0004; anti-TNF + BABIM vs. BABIM, P < 0.00014). The beneficial effect on C. obtained by administering these two agents in concert was also demonstrable on day 4, though at this time point the effect was less prominent (Ccr; anti-TNF + BABIM vs. NRS 0.05 <P < 0.1; anti-TNF + BABIM vs.
anti-TNF P < 0.05).
Effect of BABIM on cytotoxicily of rMuTNF in vitro BABIM was not toxic to the L929 cell line at concentrations of l0-to 10-M in incubation periods of up to 72 hours. In the present study even l0-M BABIM caused no notable suppression of cytolytic activity of rMuTNF in the system employed.
In these experiments BABIM was supplemented on a daily basis to the original concentration in the well since this inhibitor has been observed to loose activity in plastic.
Renal histopathology Daily administration of anti-TNF and/or BABIM to rats with the AA-NTSN did not prevent development of glomerular hypercellularity, as observed in nephritic rats receiving NRS vehicle (PBS). Conversely, glomerular necrosis, fibrin deposition and damage to the GBM were significantly reduced in the AA-NTSN by both agents (Fig. 5, Table 2 , anti-TNF vs. NRS, P < 0.01; BABIM vs. NRS, P < 0.0025). Combined administration of anti-TNF antiserum plus BABIM caused a more striking reduction in these three parameters of renal injury than observed with either agent in isolation, though in case of BABIM the difference was not statistically significant ( Table 2, anti-TNF vs. anti-TNF + BABIM, P < 0.01; BABIM vs.
anti-TNF + BABIM, 0.05 <P < 0.1). BABIM was somewhat more effective than anti-TNF antiserum (0.2 mI/day) in ameliorating glomerular necrosis (anti-TNF vs. BABIM, P < 0.02), although equivalent results could have been obtained with a higher dose of anti-TNF. Renal histopathology in rats with the AA-NTSN treated with NRS was analogous to that observed in rats treated with PBS alone, suggesting therefore, that the administration of rabbit serum did not contribute to histologic changes in AA-NTSN (incidence of glomerular necrosis: NRS 9.92% 4.99%, PBS 8.00% 4.65%; glomeruli with crescents: NRS 2.33% 2.40%, PBS 2.37% 1.79%).
Crescent formation is not a prominent feature in this model Abbreviations are: AA-NTSN, the accelerated autologous form of nephrotoxic serum nephritis; SD, standard deviation; NRS, non-immune rabbit serum; anti-rMuTNF anti-serum, rabbit anti-serum to recombinant murine tumor necrosis factor-alpha with neutralizing titer of 1:32,000.
Day4
Day8 system. Few crescents are observed by day 8 postinduction. Thus, though BABIM and/or anti-TNF antiserum tended to reduce the frequency of crescents, some of these differences fail to achieve statistical significance ( Table 2, Figure 6 . Renal sections of kidneys of all groups of rats treated with anti-TNF antiserum stained with FITC labelled antibodies to rabbit IgG, C3 were either negative, or revealed only faint granular staining. Analysis using fluorescent probes for rat 1gM and C3 displayed only weak granular staining, indicating that these components of autologous rat serum did not considerably bind to glomeruli of rats with AA-NTSN.
Electronmicroscopic studies failed to disclose significant qualitative differences in glomerular histology. The principal ultrastructural findings in treated and control AA-NTSN rats were as follows: damage to the lamina rara interna, variable fusion of epithelial foot processes as well as linear and granular subepithelial (rarely subendothelial or mesangial) localization of electron-dense deposits. EM documented equivalent location of macrophages in experimental and control nephritic rats. 1.00 1.16 antiserum (N = 
Data were estimated from PAM-stained sections.
All cases had proliferative glomerulonephritis and there were no significant differences in the degree of hypercellularity between groups.
assessed to determine whether the various treatment regimens under study modulated the host humoral immune response, a matter of some importance, since circulating antibody levels have been shown to be closely correlated with glomerular injury in this model system [20] . Anti-sheep antibody levels, measured by solid phase radiometric assay on days 4 and 8 postinduction AA-NTSN in treated and control rats, expressed as cpm, were Somewhat to our surprise, rats with AA-NTSN receiving both anti-TNF and BABIM were found to have significantly higher antibody levels than NRS controls on day 8 (anti-TNF + BABIM1154±221,N5;NRS896± l0l,N=5;P<0.025; Exp. VIII). In the same experiment anti-sheep IgG antibody titers in anti-TNF or BABIM treated rats were equivalent to control (anti-TNF 910 146, N = 5; BABIM 941 242, N = 5). Although, on day 4, antibody levels in anti-TNF + BABIM treated AA-NTSN rats tended to be higher than the levels measured in other groups, such differences were not statistically significant (data not shown). 
Discussion
Our results demonstrate that heterologous antiserum, neutralizing cytotoxic activity of TNF in vitro, reduced glomerular injury in vivo when administered to rats with the accelerated autologous nephrotoxic serum nephritis. This is, to our knowledge, the first direct evidence implicating TNF in the physiopathology of immune glomerulonephritis and the first successful attempt to reduce intensity of a glomerular inflammatory reaction with an antiserum against a soluble inflammatory mediator.
These data are, however, consistent with our previous observation that TNF is generated and released by glomeruli of nephritic rats [9] , the known pathogenic potential of this cytokine [10] [11] [12] [13] [14] [15] [16] [17] In the present study anti-TNF antiserum effected a dosedependent reduction in albuminuria without impairing glomerular filtration. Histologic examination revealed a diminution in glomerular necrosis and fibrin deposition, but no apparent effect on the appearance of glomerular hypercellularity noted in this model, indicating that monocyte recruitment to renal tufts was not affected by systemic neutralization of TNF. Therefore, although we cannot exclude a possibility that anti-TNF antiserum might have acted systemically, it is conceivable that it operated primarily at the glomerular level to inhibit local proinflammatory activity of this cytokine.
Moreover, we have documented that anti-TNF antiserum did not affect levels of circulating antibody to sheep immunoglobulin G and demonstrated that the intensity of glomerular deposition of autologous antibody against the GBM-bound sheep antiserum was the same in treated and control animals. In the same light we have confirmed that rabbit anti-TNF antiserum did not affect renal binding of sheep anti-rat GBM antibody in vivo. We infer from these data that anti-TNF antiserum did not modify humoral immune reactions bearing upon pathogenesis of this nephritis model. Additional studies were performed to document that the administration of crude rabbit serum did not modify immunopathogenic correlations in this model system. Finally, we confirmed that identical reduction in glomerular injury was observed when the IgG fraction of anti-TNF antiserum was administered to rats with the AA-NTSN to limit delivery of exogenous proteins and exclude the possibility that other factors present in sera of rabbits repeatedly inoculated with rMuTNF might have affected our results.
We are uncertain which of the various proinfiammatory activities ascribed to TNF was inhibited by the neutralizing antiserum obtained in this study. A marked reduction in gbmerular fibrin deposition (Table 2) , consequent to anti-TNF administration, may be due to interference with the TNFinduced expression of procoagulant activity by endothelial cells [12] . TNF has been reported to be directly toxic to vascular endothelium [26] , to augment cytotoxic activity of macrophages [15] and stimulate production of proteolytic enzymes [13] .
Clearly, modulation of any of these pathophysiologic processes may be responsible for functional and histologic renal abnormalities in this model system.
We suggest, further to our previous report [9] , that TNF may be produced, at least in part, by monocytes/macrophages infiltrating glomerular tufts. Indeed, an antimacrophage antiserum reduced glomerular mononuclear phagocyte infiltration and abrogated renal injury in a passive autologous form of nephrotoxic serum nephritis in rabbits [27] . Nonetheless, it is possible that other cell types may be involved, as we have recently accumulated evidence indicating that normal, contractile mesangial cells spontaneously release TNF in culture (manuscript submitted). Further, a resident population of mononuclear phagocytes has been identified in normal rat mesangium [28] and this must be considered as a potential source of TNF.
The application of a protease inhibitor in this study was inspired, at least in part, by the observation that only about 50% of daily albumin losses were inhibitable by anti-TNF. Given the evidence that neutral proteases may damage the GBM [29] , we set out to examine the possibility that protease inhibitor may exert additive/synergistic effects on glomerular injury in the AA-NTSN. An amidine-type synthetic antagonist (BABIM) of proteolytic enzymes sharing trypsin-like properties was chosen, since this compound has been shown to be safely and successfully used in vivo to ameliorate the course of immune complexmediated glomerular injury in mice [19] . Our results indicate this protease inhibitor is capable of diminishing gbomerular permeability to proteins in AA-NTSN to the degree comparable to that of anti-TNF, although results of statistical analysis may suggest that BABIM was somewhat more effective. It has also reduced the intensity of glomerular necrotic changes similarly to an immune complex nephritis model studied by Jennette et al [19] . Indeed, the overall effects of anti-TNF antiserum and BABIM on the progression of glomerular injury in the AA-NTSN were virtually indistinguishable. There is no evidence in support of a presumption that BABIM caused reduction in albuminuria through a direct interference with enzymes digesting GBM. It, however, seems conceivable that, given its antinecrotic effect, BABIM might have exerted local inhibition of serum proteolytic cascades generating kinins and activating coagulation and fibrinolysis, as suggested by Jennette et al [19] . BABIM has potentiated the beneficial effect of anti-TNF on proteinuria and renal histopathology. Moreover, both agents applied in concert produced significant improvement of renal function in rats with AA-NTSN. This phenomenon, not seen in animals treated with anti-TNF or BABIM alone, indicates apparent synergy of these two agents in abrogation of glomerular inflammatory injury. Simultaneous administration of anti-TNF and BABIM resulted in significant increase of serum autologous nephritogenic antibody levels, an observation noted exclusively in this experimental population. In fact, it has been demonstrated in a previous report from this laboratory [20] that serum autobogous antibody levels are, by day 8 of AA-NTSN, inversely correlated with the magnitude of proteinuria, and this is due to urinary losses of immunoglobulins. Hence, although rat urine IgG was not measured in this study, we infer that the elevated levels of antibody to heterologous (sheep) immunoglobulin (day 8) further confirm the remarkable antiproteinuric effect of combined therapy with anti-TNF and BABIM, rather than indicating that antibody production is enhanced in these animals.
The possibility that BABIM may mediate its beneficial effect on AA-NTSN by directly inhibiting TNF activity was entertained briefly, since other protease inhibitors (that is, TLCK) have been reported to effectively protect established cell lines from cytolysis by TNF [18] . Results of our tests indicate that BABIM does not interfere with the cytotoxic activity of TNF in vitro, and thus it seems unlikely that it might have directly inhibited proinflammatory effects of TNF in vivo. The reasons for the discrepancy between results of testing TNF sensitivity to neutralization by protease inhibitors obtained by Ruggiero, Johnson and Baglioni [18] , and these presently reported are not immediately obvious. Nonetheless a basic difference in experimental design relying on target cell pretreatment with inhibitor before adding TNF [18] , opposed to coincubation of TNF and inhibitor with target cells performed in our study, may be of significant explanatory relevance. Additionally, even a slight difference in sensitivity of target proteases to inhibition by BABIM and other inhibitors employed by the Ruggiero group might have resulted in a major discrepancy of the final effects.
Although the present report documents that TNF is an important mediator of immune glomerular injury in at least this model of experimental immune renal disease, it is clear that this factor is but one of many soluble mediators involved in pathophysiology of acute gbomerulonephritis. In this report we further confirm the role of proteases in the pathogenesis of experimental nephritis. Augmented release of arachidonic acid metabolites have been found to be responsible for the early decline in GFR in nephrotoxic serum nephritis [30] . Platelet activating factor (PAF), another lipid derivative, have been documented by ourselves and others [31, 32] to affect gbomerular permselectivity to proteins and renal histology in the AA-NTSN and other experimental nephritis models. It is of note that TNF is reported to induce PAF release from endothehal and other cell types [32] and therefore these two mediators may be linked in the immune/inflammatory tissue injury. Nonetheless, the present documentation of the participation of TNF in the pathogenesis of experimental immune glomerulonephritis clearly underlines the importance of further studies to elucidate the exact mechanisms of TNF-induced tissue injury and to delineate effective strategies to counter its pharmacologic effects.
